Compare QUAD & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUAD | CCCC |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.3M | 404.7M |
| IPO Year | 2010 | 2020 |
| Metric | QUAD | CCCC |
|---|---|---|
| Price | $9.64 | $3.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $9.93 | ★ $12.20 |
| AVG Volume (30 Days) | 341.3K | ★ 1.8M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.71% | N/A |
| EPS Growth | ★ 150.47 | 16.45 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $2,419,900,000.00 | $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $73.08 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $5.12 | $1.69 |
| 52 Week High | $11.15 | $5.17 |
| Indicator | QUAD | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 38.87 |
| Support Level | $7.15 | $3.38 |
| Resistance Level | $11.01 | $3.91 |
| Average True Range (ATR) | 0.37 | 0.16 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 17.18 | 16.97 |
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.